Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 85.21
+2.84 (3.45%)
At close: Aug 15, 2025, 2:57 PM CST
SHA:688192 Revenue
Dizal (Jiangsu) Pharmaceutical had revenue of 159.64M CNY in the quarter ending March 31, 2025, with 96.32% growth. This brings the company's revenue in the last twelve months to 438.22M, up 153.88% year-over-year. In the year 2024, Dizal (Jiangsu) Pharmaceutical had annual revenue of 359.90M with 294.24% growth.
Revenue (ttm)
438.22M
Revenue Growth
+153.88%
P/S Ratio
89.33
Revenue / Employee
514.35K
Employees
852
Market Cap
39.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 359.90M | 268.61M | 294.24% |
| Dec 31, 2023 | 91.29M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 10.29M | -17.48M | -62.95% |
| Dec 31, 2020 | 27.76M | -13.26M | -32.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| WuXi AppTec | 41.48B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |